SCHEDULE 13G/A: Lagoda Investment Management Discloses 8.18% Passive Stake in VolitionRX Limited
Beneficial Ownership Report
Lagoda Investment Management, L.P. has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.18% in VolitionRX Limited as of December 31, 2024.
Summary
- Lagoda Investment Management, L.P. (the "Reporting Person") has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in VolitionRX Limited.
- As of December 31, 2024, the Reporting Person beneficially owned 7,576,000 shares of Common Stock of VolitionRX Limited.
- This ownership represents 8.18% of the outstanding Common Stock of VolitionRX Limited.
- The Reporting Person, an investment adviser, holds sole voting power and sole dispositive power over all 7,576,000 shares.
- The filing confirms that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a Schedule 13G is a routine disclosure, the presence of a significant passive institutional investor can be seen as a positive signal of confidence in the company's long-term prospects, without indicating any immediate negative intentions.
Positives
- The disclosure of a significant 8.18% passive stake by an institutional investment firm like Lagoda Investment Management, L.P. can be viewed as a vote of confidence in VolitionRX Limited.
- The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, indicating a passive, long-term investment approach.
Future Outlook
The document does not provide any forward-looking statements or guidance from VolitionRX Limited or Lagoda Investment Management, L.P. beyond the disclosure of current ownership.
Industry Context
This filing is a routine disclosure of a significant passive ownership stake by an investment firm in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape for VolitionRX Limited.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder, potentially influencing investor confidence and perception of the stock's stability.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 92,664,812 shares of VolitionRX Limited Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2024-11-14 | Date VolitionRX Limited filed its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. |
| 2024-12-31 | Date of event which required the filing of this Schedule 13G Amendment, reflecting the beneficial ownership position. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed and filed by Lagoda Investment Management, L.P. |
Keywords
VolitionRX Limited, Lagoda Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Stake, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.